A single center’s experience of the extrapulmonary neuroendocrine carcinomas

OBJECTIVE: Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC.
METHODS: This retrospective study was conducted based on the medical records from January 2010 to March 2020. Eligible patients had been pathologically diagnosed with EP-NEC.
RESULTS: Forty-seven patients were included in the study. About 72.3% (n=34) of the patients were diagnosed with metastatic disease at the first diagnosis. The most common primary tumor site was the stomach. The median progression-free survival (PFS) of the patient group, who received the combination of platinum/etoposide, was 5.83 months (95% CI 4.46–7.20), whereas the median OS of the patients, who were found to have metastatic disease at the first diagnosis, was 13.6 months (95% CI 9.01–18.18). There was no difference in PFS and OS between patients with and without liver metastasis.
CONCLUSION: The outcome of advanced EP-NECs with platinum/etoposide chemotherapy remains poor. Obviously, there is a need for new, more effective treatment options.

Akciðer dýþý nöroendokrin karsinomlar: Tek merkez deneyimi

Giriþ: Ekstra-pulmoner nöroendokrin karsinomlar (EP-NEK) nadir görülen tümörlerdir ve standart tedavileri netleþmemiþtir. Bu çalýþmada amaç platin-etoposid kombinasyonunun sað kalým ve tedavi etkinliðini araþtýrmaktýr.
Yöntem: Bu retrospektif çalýþma, Ocak 2010-Mart 2020 yýllarý arasýndaki týbbi kayýtlar ile yapýldý. Patolojik olarak EP-NEK tanýsý olan hastalar dahil edildi.
Bulgular: Çalýþmaya 47 hasta dahil edildi. Hastalarýn %72.3’ü (n=34) ilk tanýda metastatikti. En sýk primer tümör yerleþim yeri mideydi. Platin/etoposid alan hastalarda ortanca progresyonsuz sað kalým (PSK) 5.83 ay idi (95% CI 4.46-7.20). Ýlk tanýda metastatik olan hastalarda ortanca genel sað kalým (GSK) ise 13.6 ay idi (95% CI 9.01-18.18). Karaciðer metastazý olan ve olmayan gruplar arasýnda PSK ve GSK farký yoktu.
Sonuç: EP-NEK tanýlý hastalarda platin/etoposid tedavi sonuçlarý yüz güldürücü deðildir. Yeni ve daha efektif tedavilere ihtiyaç olduðu aþikardýr. (NCI-2020-0334.R1)